Zhitong Financial App News, Zejing Pharmaceutical (688266.SH) issued an announcement. Recently, the company received the “Notice of Acceptance” approved and issued by the National Drug Administration (NMPA), and the new drug marketing application (NDA) submitted by the company for the treatment of active ankylosing spondylitis was accepted. This is the third indication for gemaxitinib hydrochloride tablets to apply for the marketing of a new drug. Gicaxitinib hydrochloride (former name: jacketinib hydrochloride) is a novel JAK inhibitor drug independently developed by the company, and the company has independent intellectual property rights for this product.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.